HIP-Vax

The demand for viral vector-based products is growing rapidly. However, there are still manufacturing challenges which hamper the development of these promising new therapies. A major problem is low product yields. For many medical applications, a certain minimal dose of product is needed to have a clinical effect. With low production yields, it is a challenge to get enough product concentrated in one syringe.

Additionally, low production efficiency necessitates large volume production to obtain sufficient doses, resulting in high cost of goods. For instance, many viral vectors are produced by adherent cells that are cultured in cell factories, but this legacy technology can only be scaled out rather than scaled up, and no significant reduction of cost of goods can be achieved when larger numbers of cell factories are used to obtain more product. To address this problem, we developed highly intensified manufacturing processes.

By means of bioprocess intensification, we are able to:

Reduce facility footprint (CAPEX),Reduce amount of labor and consumables required (OPEX),Reduce total process times. HIP-Vax offers a complete solution for a variety of viral vector platforms, including adenoviral vectors and lentiviral vectors. The package includes:

cGMP compliant protocols for intensified production and purification processes,Optimized producer cell lines, and cGMP compliant virus seeds. The processes are designed to deliver large volumes of viral vector drug substance at a low cost of goods.